SENXUAN(BJ:830946)2024-05-13 23:04Group 1: Company Performance - The company's revenue and net profit experienced a decline in 2023 due to decreased demand for certain products and intensified competition, leading to a significant drop in sales prices [4] - The company plans to implement a "dual circulation" strategy to maintain existing markets and explore new ones, while enhancing its competitive edge through cost management and new product development [4] Group 2: Fundraising and Investment Projects - The company has changed its fundraising project from "20 tons/year of Ritonavir and 30 tons/year of Dipyridamole raw material expansion project" to "annual production of 40 tons of Ritonavir and 60 tons of Buflomedil raw material construction project," with an investment of 6.0448 million yuan so far [4] - The company is focused on efficient investment strategies, emphasizing safety and quality in future investments while continuing to operate existing projects [8] Group 3: ESG and Corporate Governance - The company is preparing to disclose an ESG report, focusing on organizational structure, historical data collection, and cultural transmission [4] - The company aims to enhance its corporate governance and maintain good communication with capital market participants to improve its market value [6] Group 4: Market and Product Development - The new drug Letermovir has not yet generated sales, as discussions with downstream formulation manufacturers are ongoing [5] - The company is committed to its development strategy of refining raw materials, specializing in intermediates, expanding new materials, and positioning itself in generic and innovative drugs [4][8] Group 5: Operational Challenges - The subsidiary in Ningxia has not resumed operations, and the company is actively coordinating the resumption process [7] - The company holds 500 to 600 million yuan in cash and remains optimistic about the pharmaceutical industry's future, focusing on strategic investments [8]